Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

NCT07379827 · clinicaltrials.gov ↗

RECRUITING

Status

1500

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Xanomeline and trospium chloride (KarXT)

Sponsor

Bristol-Myers Squibb